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Abstract
Background
Intrahepatic cholestasis of pregnancy (ICP) is the commonest gestational liver disease. The
risk of adverse fetal outcome has been associated with the severity of maternal hyperchola-
nemia after diagnosis.
Objective
To investigate whether there is a relationship between the severity and timing of onset of
hypercholanemia and the risk of meconium-stained amniotic fluid (MSAF) and adverse neo-
natal events.
Study design
The study included 382 pregnancies complicated by ICP managed at a referral hospital in
Buenos Aires (Argentina) between June 2009 and December 2013. The patients were clas-
sified into three groups according to the severity of hypercholanemia at diagnosis; mild (10–
19.9 μmol/L), moderate (20–39.9 μmol/L) and severe (40 μmol/L). Their clinical character-
istics and pregnancy outcomes were investigated in a prospective observational study.
Results
Higher risk of MSAF was observed when ICP appeared early in gestation or when hypercho-
lanemia was more severe. Taking both parameters into account an MSAF risk factor (MRF)
was defined. Based on a model of positive/negative predictive values, a cut-off point of
MRF = 3 was selected, which prioritized sensitivity versus specificity. In ICP patients with
MRF>3, the probability of MSAF was enhanced 4-fold. An increase in the frequency of
MSAF was also associated with higher serum levels at diagnosis of alanine transaminase,
alkaline phosphatase and direct bilirubin.
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Conclusions
The risk of MSAF is associated not only with the magnitude of hypercholanemia at diagnosis
but also with the early gestational onset of raised maternal serum bile acids.
Introduction
Intrahepatic cholestasis of pregnancy (ICP) is usually diagnosed in the third trimester of
gestation, although it may present as early as the first trimester. It typically resolves without
treatment after delivery [1]. The etiopathogenesis of ICP involves genetic, hormonal and envi-
ronmental factors [2], and diagnosis is based on the presence of pruritus and fasting elevated
serum bile acid concentrations (10 μmol/L), i.e., hypercholanemia. ICP is not usually associ-
ated with immediate life-threatening complications for the mother, although recent studies
have suggested that ICP patients have a significantly higher risk of developing gestational dia-
betes [3]. Also long term complications of ICP, such as hepatobiliary diseases, autoimmune-
mediated diseases, cardiovascular problems and cancer have been reported [4,5].
As demonstrated in animal models, exposure to pathologically high levels of bile acids
affects normal fetal development, in particular adversely impacting hepatobiliary function
[6,7], with persistent abnormalities for several weeks after birth [8]. Ursodeoxycholic acid
(UDCA) administration partially prevents the deleterious effects of maternal cholestasis on rat
placenta [9,10], but has no effect on the altered expression of genes involved in neonatal hepa-
tobiliary function [10].
The severity of hypercholanemia has been associated with higher risk of serious adverse
events for the fetus, such as spontaneous and iatrogenic preterm delivery, fetal distress and
intrauterine fetal death, all of which occur more frequently in pregnancies with higher peaks of
maternal hypercholanemia [11–13]. High bile acid levels have also been associated with
increased risk of MSAF [14]. This is very relevant because the exposure of fetal lung to toxic
levels of these molecules can result in lung injury, through alteration of secretory phospholi-
pase A2 [15,16].
The risk of perinatal mortality has been shown to be reduced by delivery at 36 weeks of ges-
tation as compared with expectant management [17], although this study did not consider bile
acid concentrations when deciding about timing of delivery [18]. Another study using a deci-
sion-analytic model to determine the optimal gestational age for delivery of women with ICP
proposed that immediate delivery at 36 weeks of gestation without amniocentesis or cortico-
steroid administration reduced neonatal morbidity and mortality [19]. Early induction of
labor at 37 weeks of gestation was found justified in high-risk ICP (40 μmol/L total bile acid
concentration) and only a reduction in birth weight was found compared to women with
lower serum bile acids [20]. A recent meta-analysis has shown that the close monitoring of
ICP patients and treatment with UDCA are beneficial and account for a reduction in the rate
of adverse pregnancy outcomes reported in the last years [21]. Furthermore, ICP is associated
with long-term effects on the health of the offspring, including susceptibility to increased adi-
posity and metabolic disease [22].
Changes in serum levels of estrogens [23] and progesterone derivatives have been described
in asymptomatic hypercholanemia of pregnancy [24] and ICP [25], but no clear association
with the severity of hypercholanemia has been reported except for progesterone sulfates,
which have been proposed as prognostic indicators for ICP [26].
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The most popular way of establishing the severity of ICP is based on the magnitude of the
highest peak of serum bile acid levels measured at any time after diagnosing ICP, usually late
in the patient follow-up before delivery. A correlation between the degree of hypercholanemia
and the occurrence of adverse fetal events was found [11–13].
However, by doing so, some important information has not been usually considered, such
as i) the gestational age; ii) the degree of hypercholanemia at diagnosis, iii) whether the mater-
nal serum levels of bile acids were corrected during gestation, and iv) the length of time the
placenta and fetus are exposed to elevated bile acid levels in maternal blood.
The aim of the present study was to investigate whether there is a relationship between
severity of hypercholanemia and the gestational week when it appears, and the risk of MSAF
and adverse neonatal outcome in ICP pregnancies. We also evaluated whether treatment with
UDCA reduces this risk.
Material and methods
Patient selection
This investigation was conducted using data collected prospectively from June 2009 to Decem-
ber 2013 at the Ramo´n Sarda´ Mother’s and Children’s Hospital in Buenos Aires (Argentina).
Women with fasting hypercholanemia (serum bile acid levels10 μmol/L) and pruritus of
unexplained cause were invited to participate in the study. The exclusion criteria were: patients
with any other hepatic disease or disease affecting liver tests, multiple-birth pregnancies or
deliveries at another institution. Written informed consent from all patients was obtained. The
study was reviewed and approved by the Medical Ethic Committee of the Ramo´n Sarda´
Mother’s and Children’s Hospital (2009/03/12).
Definition of groups
According to the magnitude of hypercholanemia at diagnosis, which was measured with an
enzymatic colorimetric method (Randox Laboratories, Crumlin, UK) [25], the patients were
classified into three groups. In addition to the well-recognized level of severe ICP (40 μmol/
L), two additional groups of mild (10–19.9 μmol/L) and moderate (20–39.9 μmol/L) ICP were
defined for fine-tuning of the relationship between hypercholanemia and adverse outcome.
Maternal age, parity, and the following adverse events were evaluated: stillbirth, perinatal
death (between week 24 of gestation and 4 weeks after delivery), meconium aspiration syn-
drome (babies with infiltrates on chest X-ray), gestational age at delivery, preterm birth (<37
weeks of gestation, both spontaneous and elective), MSAF, placental abruption, asphyxia (arte-
rial pH <7.05 and base deficit of>12 mmol/L or arterial pH <7.0), altered fetal vitality (5 min
Apgar<7), fetal well-being (normal cardiotocograph trace), and intensive care unit admission.
Information concerning the occurrence of diabetes, pre-eclampsia, gestational hypertension,
anemia, and other pathologies was also retrieved from medical records.
To have a complete picture of the consequences of this pathology for the fetus, both
severe and mild clinical alterations were included in the evaluation of the outcome of ICP
pregnancies.
The infants that were small for gestational age (SGA) were defined as having a birth weight
<10th centile and those that were large for gestational age (LGA) as having birth weight >90th
centile, after correction for sex, parity and gestational age according to the Ramo´n Sarda´ Hos-
pital growth charts. As part of the protocol of management of these patients in the hospital,
maternal blood samples were collected twice per week from the time of diagnosis until delivery
and two more samples were obtained 1–2 days and four weeks after birth.
Prediction of meconium-stained fluid in ICP
PLOS ONE | https://doi.org/10.1371/journal.pone.0176504 April 24, 2017 3 / 15
Meconium risk factor (MRF) was defined as the ratio between serum bile acid concentra-
tions (SBAd in μM) and the gestational age (GAd in weeks), both at the time of diagnosis, i.e,
MRF = SBAd/GAd. A model of predicted positive and negative values was elaborated to select
the cut-off value.
Statistical analysis
Where the data are shown as means±SD, an ANOVA test was performed and the Bonferroni
method of multiple-range testing was used to calculate the statistical significance of differences
among groups. Categorical variables were compared with Chi-squared or Fisher’s exact tests.
A probability of<0.05 was considered statistically significant. Stata software 11 (StataCorp,
College Station, Texas, USA) was used for statistical analyses. The study is reported according
to STROBE guidelines.
Results
All pregnancies leading to delivery during the period of this study (n = 30,078) were screened
for ICP if women reported pruritus. Of a total of 522 women with pruritus of not identified
cause (Fig 1), 63 did not participate in the study, and 77 were excluded because their follow-up
was interrupted (n = 19) or due to their particular characteristics other than ICP (n = 58) that
could affect perinatal complications (Fig 1). Patients that completed the study (n = 382) were
classified based on the mothers’ serum bile acid concentrations at diagnosis as having mild
(n = 183), moderate (n = 115) or severe (n = 84) ICP. Table 1 shows the clinical and demo-
graphic characteristics of these patients.
Mean maternal age (26.0±6.5 years) was lower than in previous series [12,13], but similar to
that of the general population of pregnant women attending this hospital. Mean gestational
age at diagnosis was 33.6±3.6 weeks. Most cases were diagnosed between 32 and 37 weeks,
although 18.8% were diagnosed later, and 21.3% earlier in pregnancy (Table 1). A trend for
less severe hypercholanemia was found when the diagnosis was made closer to term.
ICP was diagnosed in one third of the patients in their first pregnancy (Table 1), while two-
thirds of patients had at least one previous pregnancy lasting for more than 20 weeks. Analysis
of the history of adverse events in these parous patients revealed frequent miscarriages (S1
Table) and gestational trophoblastic disease (one mole). In addition, 37.4% patients had a his-
tory of ICP, with 12.4% having had fetal death, and 28% preterm delivery (S1 Table). Interest-
ingly, among women with very early diagnosis (<24 weeks), 67% had a history of ICP in
previous gestations, and 33% had a history of stillbirth.
Maternal rates of co-morbidities were similar among all groups (Table 1). Five patients had
hypothyroidism, but since no routine screening of thyroid disease in pregnant women is
carried out at this hospital the data could underestimate the frequency of thyroid disease.
In recent years the number of immigrants from bordering countries has increased in
Argentina and represented 43% of the total number of women attending the hospital between
2009 and 2013 (Table 1). The prevalence in the overall ICP population was1.5%, with no dif-
ferences in geographical origin.
S2 Table shows the complete profile of serum biochemical parameters evaluated at diagno-
sis. There was a significant increase in direct bilirubin in cases with more severe hypercholane-
mia, while no changes in total bilirubin, transaminases, γ-glutamyl-transpeptidase, alkaline
phosphatase and total cholesterol, were found.
Most women diagnosed with ICP (77.9%) received treatment with UDCA (Table 1, Fig 2)
at a dose of 300 mg three times a day plus the antihistamine dexchlorpheniramine to alleviate
pruritus. The length of UDCA treatment varied from 1 to 150 days and started the day of
Prediction of meconium-stained fluid in ICP
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diagnosis, even when elective delivery was chosen. Almost 50% were treated for<2 weeks (Fig
2), and only 20 for more than two months. The administration of iron supplement (ferrous
sulfate) and levothyroxine corresponds to patients with anemia and hypothyroidism,
respectively.
Fig 1. Flow chart of ICP cases included in the study. Flow chart showing the intrahepatic cholestasis of pregnancy
(ICP) cases at the Mother’s and Children’s Hospital, Buenos Aires, from June 2009 to December 2013, and reasons for
the exclusion of some patients from the study.
https://doi.org/10.1371/journal.pone.0176504.g001
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The obstetric outcome is shown in Table 2. Mean gestational age at delivery was similar in
severe cases as compared to mild cases. In 353 neonates preterm birth and neonatal weight
was categorized. Difference between gestational age calculated from the last menstrual period
and the first ultrasound screening was lower than one week. Preterm births occurred in 225
ICP pregnancies (63.7%), much more frequently than in other recent studies [13,17]. Consid-
ering these preterm births, 16% were spontaneous and the frequency was similar in patients
with different degrees of ICP severity. In 84% there was elective induction of labor due to ICP.
Table 1. Demographic and clinical characteristics of patients.
Demographics Intrahepatic cholestasis of pregnancy
Total (n = 382) Mild (n = 183) Moderate (n = 115) Severe (n = 84) p-value
Maternal age, y 26.0 ± 6.5 26.6 ± 6.5 25.8 ± 6.6 26.4 ± 6.2 ns
Gestational age at diagnosis, wk 33.6 ± 3.6 34.2 ± 3.4 33.5 ± 3.5 32.8 ± 4.1 ns
Parity, n (%)
0 136 (35.6) 68 (37.2) 39 (33.9) 29 (34.5) 0.823
1 246 (64.4) 115 (62.8) 76 (66.1) 55 (65.5) 0.827
Gestational age at diagnosis, n (%)
<24 wk 6 (1.6) 3 (1.6) 1 (0.9) 2 (2.4) 0.695
24 to <28 wk 25 (6.5) 9 (4.9) 8 (7.0) 8 (9.5) 0.360
28 to <32 wk 50 (13.1) 21 (11.5) 16 (13.9) 13 (15.5) 0.635
32 to <37 wk 229 (60.0) 108 (59.0) 68 (59.1) 53 (63.1) 0.800
37 wk 72 (18.8) 42 (23.0) 22 (19.1) 8 (9.5) 0.033
Country of origin, n (%)
Argentina 229 (60) 114 (62.3) 67 (58.2) 48 (57.1) 0.660
Bolivia 75 (19.6) 28 (15.3) 29 (25.2) 18 (21.4) 0.099
Paraguay 58 (15.2) 30 (16.4) 14 (12.2) 14 (16.7) 0.560
Peru 14 (3.6) 8 (4.4) 4 (3.5) 2 (2.4) 0.718
Other 6 (1.6) 3 (1.6) 1 (0.9) 2 (2.4) 0.695
Co-morbidities, n (%)
Threatened premature labor 6 (1.6) 0 (0) 4 (3.5) 2 (2.4) 0.050
Diabetes 31 (8.1) 18 (9.8) 9 (4.9) 4 (4.8) 0.367
Preeclampsia 7 (1.8) 6 (3.3) 0 (0) 1 (1.2) 0.107
Gestational hypertension 7 (1.8) 4 (2.2) 2 (0.9) 1 (1.2) 0.850
Hypothyroidism 5 (1.3) 2 (1.1) 2 (0.9) 1 (1.2) 0.887
Iron-deficiency anemia 31 (8.1) 14 (7.7) 6 (5.2) 11 (13.1) 0.126
Other medical conditions 7 (1.8) 1 (0.5) 3 (2.6) 3 (3.6) 0.175
Pharmacological treatment, n (%)
Ursodeoxycholic acid 298 (78.0) 144 (78.7) 84 (73.0) 70 (83.3) 0.213
Dexchlorpheniramine 298 (78.0) 144 (78.7) 84 (73.0) 70 (83.3) 0.213
Ferrous sulfate 36 (9.4) 16 (8.7) 8 (7.0) 12 (14.3) 0.197
Folic acid 36 (9.4) 16 (8.7) 8 (7.0) 12 (14.3) 0.197
Alprazolan 1 (0.3) 1 (0.5) 0 (0) 0 (0) 0.580
Betametasone 120 76 (41.5) 39 (33.9) 5 (5.9) 0.000
Levotiroxine 5 2 (1.0) 2 (1.7) 1 (1.2) 0.887
Data are expressed as n (%), or mean ± SD. ns, p>0.05 comparing mild and moderate, mild and severe, and comparing moderate and severe. Other less
frequent medical conditions include Hirschsprung’s disease (mild, n = 1), syphilis (moderate, n = 2), dyslipidemia (moderate, n = 1), Chagas disease
(severe, n = 1), irritable bowel syndrome (severe, n = 1) and syphilis (severe, n = 1). Definition of ICP groups according to serum bile acid concentrations:
mild (10–19.9 μmol/L); moderate (20–39.9 μmol/L); severe (40 μmol/L).
https://doi.org/10.1371/journal.pone.0176504.t001
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Mode of delivery was determined according to the hospital Guideline for managments of ICP.
In the general obstetric population at this hospital during the same period, elective preterm
birth was 6-fold less frequent than in ICP women. There were two cases of placental abruption,
both in women with severe ICP with diagnosis at 31 and 29 weeks of gestation.
Fetal bradycardia was found in 28 cases without association with other complications. No
cases of asphyxia or stillbirth were recorded and only one perinatal death occurred in the
severe ICP group. The diagnosis of this latter case was made at 29 weeks of gestation with
maternal serum bile acids of 83 μM. Spontaneous birth occurred 2 weeks after diagnosis, after
placental abruption and detection of the presence of meconium-stained fluid. The Apgar
scores of the baby girl (950 g) were 7 and 8 at 1 and 5 minutes, respectively. She had respiratory
distress syndrome and a chromosomal abnormality (66,XXX).
Once adjusted for gestational age, no significant differences in birth weight of the neonates,
between ICP groups or with control neonates born in the hospital in the same period, were
found. The birth weight of the neonates was classified as SGA and LGA (Table 2). In this
study, 35 neonates (9.9%) were LGA (22 male/13 female); in 16 cases ICP was associated with
other pathologies. The frequency of LGA cases was 4.4% in the general population of the hos-
pital. Additionally, 6 neonates (1.7%) were SGA (2 male/4 female), four of them from women
without other pathologies (Fig 3).
Only 36/382 neonates (9.4%) were admitted to the intensive care unit due to respiratory
problems, with a similar frequency in the three groups. Severe breathing problems (hyaline
membrane disease) were observed in 5 of these babies. Another 48 neonates were sent to
Fig 2. Flow chart of management of patients. Flow chart showing distribution of women with intrahepatic cholestasis of
pregnancy (ICP) depending on whether they were not treated or treated with ursodeoxycholic acid (UDCA), together with
days of treatment.
https://doi.org/10.1371/journal.pone.0176504.g002
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medium care unit, mainly due to their malnutritional status and hyperbilirubinemia. MSAF
was found in 12.6% of all the deliveries (Table 2). This was diagnosed in half of the cases by
amniocentesis, and no cases of meconium aspiration syndrome were detected. The frequency
of MSAF was significantly higher (P = 0.019) when ICP was diagnosed at earlier gestational
ages (Fig 4A) and when delivery occurred earlier (P<0.0001) (Fig 4B). MSAF was significantly
more frequent when serum bile acid concentrations were higher at diagnosis (P = 0.0015).
This was clearly seen in untreated pregnancies (Fig 4C), in which delivery occurred sooner
(2 days) after diagnosis. The association between the severity of hypercholanemia at diagno-
sis (Fig 4C and 4D) or at birth (Fig 4E) and the presence of MSAF was modified by treatment
with UDCA (Fig 4D and 4E). In the ICP patients, severe hypercholanemia (40 μmol/L), but
also high levels of alanine transaminase (80 UI/L), alkaline phosphatase (900 UI/L) and
direct bilirubin (0.3 mg/dL) were associated with MSAF in univariate analyses of maternal
serum biochemical parameters at diagnosis, but not at delivery (S3 Table).
The rate of MSAF was significantly higher among women who underwent elective cesarean
section. This was not surprising because in 79.2% of cases the antenatal detection of meconium
Table 2. Comparison of obstetric outcomes.
Obstetric outcome Intrahepatic cholestasis of pregnancy
Total (n = 382) Mild (n = 183) Moderate (n = 115) Severe (n = 84) p-value
Gestational age at birth (wk) 35.7 ± 1.8 36.1 ± 1.7 35.6 ± 1.8 35.0 ± 2.0 ns
Birth weight (g) 2815 ± 499 2896 ± 433 2821 ± 511 2631 ± 568 ns
Neonatal sex (male/female) (n/n) 198/184 92/91 66/49 40/44 0.333
Mode of delivery, n (%)
Vaginal 158 (41.4) 80 (43.7) 47 (40.9) 31 (36.9) 0.572
Elective caesarean 224 (58.6) 103 (56.3) 68 (59.1) 53 (63.1) 0.572
Perinatal outcome, n (%)
Meconium-stained amniotic fluid 48 (12.6) 15 (8.2) 13 (11.3) 20 (23.8) 0.0015
Meconium aspiration syndrome 0 (0) 0 (0) 0 (0) 0 (0) -
Altered fetal heart rate 21 (5.5) 8 (4.4) 5 (4.4) 8 (9.5) 0.186
Placental abruption 2 (0.5) 0 (0) 0 (0) 2 (2.4) 0.028
Stillbirth 0 (0) 0 (0) 0 (0) 0 (0) -
Perinatal death 1 (0.3) 0 0 1 (1.2) 0.169
Asphyxia 0 (0) 0 (0) 0 (0) 0 (0) -
5 min Apgar <7 0 (0) 0 (0) 0 (0) 0 (0) -
Body weight/gestational age relationship, n (%)* (n = 353)* (n = 168) (n = 108) (n = 77)
Small weight for gestational age 6 (1.7) 2 (1.2) 2 (1.8) 2 (2.6) 0.724
Appropriate weight for gestational age 312 (88.4) 155 (92.3) 91 (84.3) 66 (85.7) 0.092
Large weight for gestational age 35 (9.9) 11 (6.5) 15 (13.9) 9 (11.7) 0.116
Preterm birth <37 wk, n (%)* (n = 225)* (n = 94) (n = 70) (n = 61)
Spontaneous 36 (16.0) 16 (17.0) 10 (14.3) 10 (16.4) 0.890
Elective 189 (84.0) 78 (83.0) 60 (85.7) 51 (83.6) 0.890
Admission intensive care unit 36 (16.0) 14 (14.9) 12 (17.1) 10 (16.4) 0.922
Admission medium care 48 (21.3) 25 (26.6) 12 (17.1) 11 (18.0) 0.262
Respiratory distress syndrome 36 (16.0) 14 (14.9) 12 (17.1) 10 (16.4) 0.922
Data are expressed as n (%), or mean ± SD. ns, p>0.05 comparing mild and moderate, mild and severe, and moderate and severe. Definition of ICP groups
according to serum bile acid concentrations: mild (10–19.9 μmol/L); moderate (20–39.9 μmol/L); severe (40 μmol/L).
*, 29 neonates were not included due to lack of accurate data on gestational age.
https://doi.org/10.1371/journal.pone.0176504.t002
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in amniotic fluid obtained at amniocentesis was the reason to schedule operative delivery to
prevent complications.
To evaluate the risk of MSAF in an attempt to improve the identification of patients with a
higher risk of fetal complications, a new index was calculated (see “Material and methods” sec-
tion). The MRF takes into account the two factors that were identified in the present study as
being associated with higher frequency of MSAF, i.e., the degree of hypercholanemia (direct
relationship) and gestational age at diagnosis (inverse relationship). Using a model of positive
and negative predictive values, calculation of the sensitivity and specificity for different cut-off
values of MRF was carried out (Fig 5A).
Using these criteria more useful balance between sensitivity (66.7%) and specificity
(74.5%) was obtained for MRF = 3. In untreated ICP patients MSAF frequency was signifi-
cantly lower (7.3%) in MRF negative cases than in MRF positive gestations (31.6%) (Fig 5B).
Moreover, in the MRF positive group treatment with UDCA significantly reduced the risk of
MSAF (Fig 5B).
Discussion
To our knowledge, the present study is the largest one carried out on a Latin American popula-
tion. In our series of pregnant women, the incidence of ICP was close to 1.5%. This is higher
than the incidence of 0.2–0.7% found for ICP in most European and North American series
[14,27], and lower than the reported incidence of ICP in Bolivia and Chile of 15% in older
Fig 3. Relationship between hypercholanemia and body weight at birth. Gestational age and body weight of neonates born from women with
intrahepatic cholestasis of pregnancy (ICP) with high or low weights at birth for their gestational age.
https://doi.org/10.1371/journal.pone.0176504.g003
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studies [28]. However, more recent studies in the same geographical area have reported a
lower incidence [29], consistent with our study.
The aim of the management of women with ICP is to reduce discomfort from pruritus
and to prevent adverse fetal/neonatal outcomes for which there are currently no reliable
Fig 4. Relationship between hypercholanemia and the frequency of meconium-stained amniotic fluid (MSAF).
Frequency of the presence of MSAF in pregnancies complicated by cholestasis of pregnancy classified according to
gestational age (GA) at diagnosis (A) or at delivery (B), severity of hypercholanemia (mild: 10–19.9 μmol/L; moderate:
20–39.9 μmol/L; severe:40 μmol/L) at diagnosis in women not treated (C) or women treated with ursodeoxycholic acid
(UDCA), (D), and at delivery in those treated with UDCA (E).
https://doi.org/10.1371/journal.pone.0176504.g004
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predictive tests. In borderline cases, clinicians make their decisions taking into account the
gestational age and the evolution of ICP-associated hypercholanemia. Liver function test
based on serum biochemistry profile and bile acid determinations are typically performed
every 3–7 days. Many clinicians also elect to perform intrapartum fetal heart rate monitor-
ing, although this procedure provides limited additional information to predict the
outcome.
The peak value of hypercholanemia determined during the follow-up of these patients has
been commonly used to establish the severity of ICP. Because this condition is characterized
by dynamic changes in maternal serum bile acid levels the management of these patients is
usually adapted over time. As adverse pregnancy outcomes do not occur in pregnancies where
the maternal serum bile acid concentration is <40 μmol/L [11], expectant management may
be considered for women with persistent mild hypercholanemia, i.e., from10 μmol/L to
<40 μmol/L serum bile acid concentrations. These women are commonly treated with UDCA,
which improves pruritus and serum biochemistry, including serum bile acid levels in an
important proportion of patients [30,31]. Only about a quarter of patients do not respond to
this treatment [25].
Fig 5. Evaluation of the index to predict the risk of meconium-stained amniotic fluid (MSAF). Balance between sensitivity and specificity for
different cut-off values of meconium risk factor (MRF), calculated taking into account the severity of hypercholanemia and gestational age at diagnosis (A).
Proportion of cases of MSAF in pregnancies with complications due to cholestasis of pregnancy according to a MRF cut-off value of 3 in women not
treated or treated with ursodeoxycholic acid (UDCA) (B).
https://doi.org/10.1371/journal.pone.0176504.g005
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The induction of labor before the 37th week of gestation, once fetal lung maturity has been
verified and sometimes after antenatal administration of corticosteroids to accelerate lung
maturity, is the standard protocol used at many hospitals with the aim of preventing stillbirth
[11], although this strategy increases the risk of preterm-associated complications. Compared
with expectant management, immediate delivery at 36 weeks of gestation has been reported to
reduce perinatal complications in ICP [17,19]. In the present series, the lack of cases of still-
birth from 225 women whose babies were delivered before 37 weeks of gestation supports the
beneficial effect of this strategy.
Changes in the management and close monitoring of ICP patients have reduced the fre-
quency of stillbirths from rates of 7%, some years ago [32,33] to 3.5% or less in more recent
studies [13,14,33], however, the risk of stillbirth and other less severe perinatal complications,
such as MSAF, justify the search for prognostic factors that can help clinicians to choose the
best option for each patient at each moment.
MSAF is a sign of fetal distress whose detection indicates the need for expedited delivery to
prevent babies from developing meconium aspiration syndrome if they inhale meconium-
stained fluid. This is a very rare complication, but it can be fatal and when it appears in pre-
term infants it is associated with higher neonatal morbidity [34]. In the present series, these
neonates were treated in intensive care units with close monitoring and all of them had good
outcomes.
In control pregnancies from this hospital and also in other studies [12,35], MSAF appears
more frequently in births close to term and especially in post-date deliveries; this has been
associated with a more advanced maturation of the gastrointestinal tract.
This study supports previous research demonstrating an association between MSAF and
lower gestational age both at diagnosis and at birth in ICP. The strongest association with the
occurrence of MSAF is found with higher degree of hypercholanemia at diagnosis. UDCA
treatment reduces the risk of MSAF. Moreover, the present study also supports results from a
recent study on a smaller number of ICP patients (59 women), which suggested that gesta-
tional age at diagnosis and serum bile acid levels are associated with adverse perinatal respira-
tory problems [36].
The mechanism by which high bile acid levels could cause MSAF is not clear but it has been
proposed that it could be due to stimulation of colonic motility or be a result of fetal distress
itself [37,38].
The presence of bile acids in meconium can result from bile reaching the fetal duodenum
and/or from the amniotic fluid ingested by the fetus. A recent study analyzing bile acid species
in the biliary tract and in the intestinal meconium of infants who died from miscarriage or
soon after birth reported the presence of sulfate-conjugated bile acids in the meconium but
not in gallbladder bile, which suggests that their origin probably is mainly the amniotic fluid
swallowed by the fetuses [39]. Bile acid concentrations in amniotic fluid are 70-fold higher in
ICP pregnancies than in controls [40], and are also significantly higher in the meconium of
newborns from women with ICP than in controls [41]. This supports that enhanced colonic
motility could be involved in MSAF.
An easy and accurate method for calculating the degree of the risk of MSAF would be a use-
ful tool to help the obstetrician to take decisions regarding the management of ICP patients
based on the probability of facing fetal and neonatal complications. Consequently, cases with
moderate hypercholanemia but early onset of ICP must be closely monitored. The proposed
MRF is a novel index that has proved to be reasonably useful for its incorporation into the fol-
low up of these pregnancies. Moreover, the result from calculating MRF reflects the beneficial
effect on the fetus of treating ICP patients with UDCA. However, the actual accuracy of MRF
needs to be confirmed in further prospective studies.
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